Galectin Therapeutics Inc. filings document a clinical-stage biotechnology issuer developing galectin-targeted therapeutics, including belapectin for MASH cirrhosis and portal hypertension. Form 8-K reports furnish operating results, financial condition updates, business updates, Regulation FD materials, and clinical-program disclosures tied to NAVIGATE trial presentations and corporate presentations.
The company’s proxy and governance filings cover director elections, advisory votes on executive compensation, auditor ratification, board changes, officer compensation arrangements, and annual meeting results. Its SEC records also identify GALT common stock registered on The Nasdaq Stock Market and include risk-factor references related to forward-looking clinical development and financing needs.
Galectin Therapeutics reported cash of $13.771 million and a six-month net loss of $17.152 million. Operating expenses for the six months fell to $12.522 million from $20.939 million a year earlier, driven by lower research and development spending ($9.746 million versus $17.867 million). Net cash used in operating activities improved to $14.291 million from $20.438 million. The balance sheet shows total liabilities of $132.769 million and stockholders' deficit of $(118.890 million), including $88.150 million of borrowings and accrued interest under related-party convertible lines of credit and $1.537 million of derivative liabilities. Management discloses substantial doubt about the company’s ability to continue as a going concern but states available credit and a new related-party $10 million supplemental line provide belief that planned operations can be funded through June 30, 2026.